A secondary analysis of the EVEREST trial found that adjuvant everolimus did not provide a recurrence-free or overall survival benefit in patients with localized non–clear cell RCC.

RCC had recently undergone rounds of staff layoffs and furloughs, as well as program changes as the college worked to rope in a recurring deficit that's been estimated at around $4 million.

FORT HUACHUCA, AZ – As one of the last acts of exceptionalism before becoming The Global Cyber Center, the Regional Cyber Center – CONUS (RCC-C) was honored as the 2024 Regional Cyber Center ...